[1]易长虹,袁琳波,钱 坤,等.肝动脉灌注3-溴丙酮酸阻断大鼠肝癌能量代谢的实验研究[J].介入放射学杂志,2013,(12):1027-1032.
　YI Chang? hong,YUAN Lin? bo,QIAN Kun,et al. Hepatic arterial infusion of 3?蛳 bromopyruvate to block up the energy metabolism of hepatic carcinoma： an experimental study in rats[J].journal interventional radiology,2013,(12):1027-1032.
点击复制

肝动脉灌注3-溴丙酮酸阻断大鼠肝癌能量代谢的实验研究 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2013年12期
页码:
1027-1032
栏目:
实验研究
出版日期:
2013-12-25

文章信息/Info

Title:
 Hepatic arterial infusion of 3?蛳 bromopyruvate to block up the energy metabolism of hepatic carcinoma： an experimental study in rats
作者:
 易长虹;  袁琳波;  钱 坤;  张 真;  郑传胜;  韩 萍
Author(s):
YI Chang?蛳 hong;  YUAN Lin?蛳 bo;  QIAN Kun;  ZHANG Zheng;  ZHENG Chuan?蛳 shen;  HAN Ping.
 Department of Radiology， Affiliated Union Hospital， Tongji Medical College， Huazhong University of Science and Technology， Wuhan， Hubei Province 430022， China
关键词:
 ; 【关键词】 肝细胞癌;  介入治疗;  3-溴丙酮酸;  大鼠
文献标志码:
A
摘要:
 【摘要】 目的 体外检测3-溴丙酮酸对Walker256细胞的抗肿瘤活性，体内研究经肝动脉灌注3-溴丙酮酸对大鼠肝癌的治疗作用。方法 ① 体外研究采用二苯基四氮唑溴盐噻唑蓝比色法检测不同浓度（1、5、10、25、50 μmol/L）3-溴丙酮酸对Walker256细胞的抗肿瘤活性，琼脂糖凝胶电泳检测肿瘤细胞凋亡。② 取30只雄性Wistar大鼠建立肝癌模型，并于肿瘤种植后11 d行胃十二指肠动脉逆行插管动脉灌注治疗，随机分为动脉灌注3-溴丙酮酸组（A组）、生理盐水组（B组）和丝裂霉素联合碘油栓塞组（Ｃ组）。介入术前1 d和术后第3天进行磁共振成像（MRI）检测肿瘤体积，之后处死大鼠，病理检查肿瘤坏死情况。结果 体外研究显示，1、5、10、25、50 μmol/L 3-溴丙酮酸对Walker256细胞抑制率分别为（10.9 ± 0.9）%、（18.5 ± 1.7）%、（24.2 ± 1.3）%、（40.4 ± 3.0）%、（55.1 ± 2.4）%，50 μmol/L 3-溴丙酮酸能诱导Walker256细胞凋亡。3-溴丙酮酸治疗后第3天， A、B、Ｃ组肿瘤平均体积分别为（482.98 ± 103.88）mm3、（432.44 ± 437.39）mm3、（569.79 ± 268.89）mm3， 组间差异无统计学意义（P > 0.05）。 A组中7只Ⅲ级坏死，2只Ⅳ级坏死和1只Ⅰ级坏死，B组6只均为Ⅰ级坏死，C组5只Ⅲ级坏死和1只Ⅱ级坏死， A组肿瘤平均坏死率明显高于B组，差异有统计学意义（P = 0.001），A组与C组间差异无统计学意义（P = 0.927）。结论 肿瘤能量阻断剂3-溴丙酮酸有较强的体内、外抗肿瘤作用。 

参考文献/References:

 ［1］ Liang B， Zheng CS， Feng GS， et al. Correlation of hypoxia?蛳 inducible factor 1alpha with angiogenesis in liver tumors after transcatheter arterial embolization in an animal model［J］. Cardiovasc Intervent Radiol， 2010， 33： 806 ?蛳 812.
［2］ Zhao YB， Zhen CS， Wan Q， et al. Permanent and peripheral embolization： temperature?蛳 sensitive p （N?蛳 Isopropylacrylami?蛳 de?蛳 co?蛳 butyl methylacrylate）nanogel as a novel blood?蛳 vessel?蛳 embolic material in the interventional Therpy of liver tumors［J］. Adv Funct Mater， 2011， 21： 2035 ?蛳 2042.
［3］ Brown DB， Gould JE， Gervais DA， et al. Transcatheter therapy for hepatic malignancy： standardization of terminology and reporting criteria［J］. J Vasc Interv Radiol， 2009， 20： 425 ?蛳 434.
［4］ Li X， Feng GS， Zheng CS， et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level［J］. World J Gastroenterol， 2004， 10： 2878 ?蛳 2882.
［5］ Bhardwaj V， Rizvi N， Lai MB， et al. Glycolytic enzyme inhibitors affect pancreatic Cancer survival by modulating its signaling and energetics［J］. Anticancer Res， 2010， 30： 743 ?蛳 749.
［6］ Kim W， Yoon JH， Jeong JM， et al. Apoptosis?蛳 inducing antitumor efficacy of hexokinase Ⅱ inhibitor in hepatocellular carcinoma［J］. Mol Cancer Ther， 2007， 6： 2554 ?蛳 2562.
［7］ Ganapathy?蛳 Kanniappan S， Kunjithapatham R， Geschwind JF. Anticancer efficacy of the metabolic blocker 3?蛳 bromopyruvate： specific molecular targeting［J］. Anticancer Res， 2013， 33： 13 ?蛳 20.
［8］ Wintzell M， L?觟fstedt L， Johansson J， et al. Repeated cisplatin treatment can Lead to a multiresistant tumor cell population with stem cell features and sensitivity to 3?蛳 bromopyruvate［J］. Cancer Biol Ther， 2012， 13： 1454 ?蛳 1462.
［9］ Xiao H， Li S， Zhang D， et al. Separate and concurrent use of 2 ?蛳 deoxy?蛳 D?蛳 glucose and 3?蛳 bromopyruvate in pancreatic cancer cells［J］. Oncol Rep， 2013， 29： 329 ?蛳 334.
［10］ Tang Z， Yuan S， Hu Y， et al. Over?蛳 expression of GAPDH in human colorectal carcinoma as a preferred target of 3?蛳 bromopyruvate propyl ester［J］. J Bioenerg Biomembr， 2012， 44： 117 ?蛳 125.
［11］ Liu XH， Zheng XF， Wang YL. Inhibitive effect of 3?蛳 bromopyruvic acid on human breast Cancer MCF?蛳 7 cells involves cell cycle arrest and apoptotic induction［J］. Chin Med J （Engl）， 2009， 122： 1681 ?蛳 1685.
［12］ Yin C， Qie S， Sang N. Carbon source metabolism and its regulation in Cancer cells［J］. Crit Rev Eukaryot Gene Expr， 2012， 22： 17 ?蛳 35.
［13］ Ganapathy?蛳 Kanniappan S， Vali M， Kunjithapatham R， et al. 3?蛳 bromopyruvate： a new targeted antiglycolytic agent and a promise for Cancer therapy［J］. Curr Pharm Biotechnol， 2010， 11： 510 ?蛳 517.
［14］ Vali M， Vossen JA， Buijs M， et al. Targeting of VX2 rabbit liver tumor by selective delivery of 3?蛳 bromopyruvate： a biodistribution and survival study［J］. J Pharmacol Exp Ther， 2008， 327： 32 ?蛳 37.
［15］ Ganapathy?蛳 Kanniappan S， Geschwind JF， Kunjithapatham R， et al. Glyceraldehyde?蛳 3?蛳 phosphate dehydrogenase（GAPDH） is pyruvylated during 3?蛳 bromopyruvate mediated Cancer cell death［J］. Anticancer Res， 2009， 29： 4909 ?蛳 4918.
［16］ Marín?蛳 Hernández A， Gallardo?蛳 Pérez JC， López?蛳 Ramírez SY， et al. Casiopeina Ⅱ?蛳 gly and bromo?蛳 pyruvate inhibition of tumor hexokinase， glycolysis， and oxidative phosphorylation［J］. Arch Toxicol， 2012， 86： 753 ?蛳 766.
［17］ Park HS， Chung JW， Jae HJ， et al. FDG?蛳 PET for evaluating the antitumor effect of intraarterial 3?蛳 bromopyruvate administration in a rabbit VX2 liver tumor model［J］. Korean J Radiol， 2007， 8： 216 ?蛳 224.
［18］ Jae HJ， Chung JW， Park HS， et al. The antitumor effect and hepatotoxicity of a hexokinase Ⅱ inhibitor 3?蛳 bromopyruvate： in vivo investigation of intraarterial administration in a rabbit VX2 hepatoma model［J］. Korean J Radiol， 2009， 10： 596 ?蛳 603.
［19］ Shin SW， Han H， Choo SW， et al. Hepatic intra?蛳 arterial injection of 3?蛳 bromopyruvate in rabbit VX2 tumor［J］. Acta Radiol， 2006， 47： 1036 ?蛳 1041.
［20］ Kontzoglou K， Palla V， Karaolanis G， et al. Correlation between Ki67 and breast Cancer prognosis［J］. Oncology， 2013， 84： 219 ?蛳 225.
［21］ Ota S， Geschwind JF， Buijs M， et al. Ultrasound?蛳 guided direct delivery of 3?蛳 bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic Cancer［J］. Target Oncol， 2013， 8： 145 ?蛳 151.
（收稿日期：２０１3?鄄０6?鄄11）

相似文献/References:

[1].Spontaneous regression of a giant basilar artery aneurysm in a young adult after surgical injury ：case report and literature review[J].介入放射学杂志,2007,(10):718.
　ZHANG He,LI Ming-hua,WANG Chun,et al.Spontaneous regression of a giant basilar artery aneurysm in a young adult after surgical injury ：case report and literature review[J].journal interventional radiology,2007,(12):718.
[2]李统怀,郑红枫. 子宫动脉栓塞治疗子宫瘢痕妊娠１１例[J].介入放射学杂志,2011,(11):898.
　LI Tong-huai,ZHENG Hong-feng..Clinical application of uterine artery embolization in treating uterine scar pregnancy[J].journal interventional radiology,2011,(12):898.
[3]吕维富,张爱武,周春泽,等. 子宫动脉的三维DSA表现及其最佳显示体位探讨[J].介入放射学杂志,2011,(11):853.
　LV Wei-fu,ZHANG Ai-wu,ZHOU Chun-ze,et al.3D-DSA findings of uterine artery and its optimal projection position[J].journal interventional radiology,2011,(12):853.
[4]张 靖,周少毅,陈昆山,等.经导管动脉硬化栓塞联合注射硬化治疗婴儿颌面部巨大高流量血管瘤[J].介入放射学杂志,2011,(11):848.
　ZHANG Jing,ZHOU Shao-yi,CHEN Kun-shan,et al.Transcatheter arterial sclerosing embolization with injection sclerotherapy for the treatment of huge and high-flow maxillofacial hemangiomas in infants[J].journal interventional radiology,2011,(12):848.
[5]谢小西,吕银祥,章宏欣,等. 肝动脉化疗栓塞、射频消融联合１２５Ⅰ粒子植入 治疗原发性肝癌的临床应用[J].介入放射学杂志,2011,(11):863.
　XIE Xiao-xi,LV Yin-xiang,ZHANG Hong-xin,et al.The clinical application of TACE together with RFA and 125Ⅰ seed implantation in treating hepatocellular carcinoma[J].journal interventional radiology,2011,(12):863.
[6]王铭义,王 峰. 脑灌注成像在颈动脉狭窄介入治疗中的应用[J].介入放射学杂志,2011,(11):915.
　WANG Ming-yi,WANG Feng..Application of brain perfusion imaging in interventional treatment of carotid artery stenosis[J].journal interventional radiology,2011,(12):915.
[7]杜 猛,张锦生. 介入治疗急性深静脉血栓的临床观察[J].介入放射学杂志,2011,(11):858.
　DU Meng,ZHANG Jing-sheng..Interventional therapy for acute deep venous thrombosis: a clinical observation[J].journal interventional radiology,2011,(12):858.
[8]孟庆娜,李国庆,白晓冬. 急性心肌梗死介入治疗术中恶心呕吐的护理[J].介入放射学杂志,2011,(11):913.
　MENG Qing-na,LI Guo-qing,BAI Xiao-dong..The nursing care of nausea and vomiting occurred in interventional treatment for acute myocardial infarction[J].journal interventional radiology,2011,(12):913.
[9]王海亭,蒋忠仆,周 毅,等. 透视引导下鱼肝油酸钠泡沫硬化剂治疗下肢静脉曲张３０例[J].介入放射学杂志,2011,(11):905.
　WANG Hai-ting,JIANG Zhong-pu,ZHOU Yi,et al.Fluoroscopically-guided foam sclerotherapy with sodium morrhuate for the treatment of lower extremity varices[J].journal interventional radiology,2011,(12):905.
[10]杜 鲲,管 生,胡小波,等. 原发性肝癌ＴＡＣＥ术后完全缓解病灶磁共振 ＡＤＣ值可重复性及一致性研究[J].介入放射学杂志,2011,(11):867.
　DU Kun,GUAN Sheng,HU Xiao-bo,et al.Magnetic resonance apparent diffusion coefficient values of the completely remitted lesions of primary hepatocellular carcinoma after TACE: a study of their repeatability and consistency[J].journal interventional radiology,2011,(12):867.
[11]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(12):974.
[12]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(12):177.
[13]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(12):206.
[14]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(12):333.
[15]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(12):469.
[16]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(12):636.
[17]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
　YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(12):381.
[18]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(12):520.
[19]赵 松,陈学春,龙清云,等. 经肝动脉化疗栓塞联合射频消融治疗肝细胞癌疗效荟萃分析[J].介入放射学杂志,2013,(11):908.
　ZHAO Song,CHEN Xue? chun,LONG Qing? yun,et al. Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma： a systematic review and Meta analysis[J].journal interventional radiology,2013,(12):908.
[20]韩聚强,范公忍,任永强,等. 不同微创介入治疗原发性肝癌对机体T细胞免疫功能的影响[J].介入放射学杂志,2014,(03):218.
　HAN Ju? qiang,FAN Gong? ren,REN Yong? qiang,et al. The influence of different micro?蛳 injury interventional treatments on the T lymphocyte immune function in patients with primary hepatocellular carcinoma[J].journal interventional radiology,2014,(12):218.

备注/Memo

备注/Memo:
（收稿日期：２０１3-０6-11） 
更新日期/Last Update: